{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:54:44Z","timestamp":1772780084216,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T00:00:00Z","timestamp":1205539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s00417-008-0781-z","type":"journal-article","created":{"date-parts":[[2008,3,14]],"date-time":"2008-03-14T07:56:10Z","timestamp":1205481370000},"page":"843-848","source":"Crossref","is-referenced-by-count":10,"title":["The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity"],"prefix":"10.1007","volume":"246","author":[{"given":"Ronen","family":"Rabinowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pri-Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Spierer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,15]]},"reference":[{"key":"781_CR1","doi-asserted-by":"crossref","unstructured":"Aydogan S, Celiker U, Turkcuoglu P, Ilhan N, Akpolat N (2007) The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia\/reperfusion injury. Graefes Arch Clin Exp Ophthalmol. Sep 3 (Epub ahead of print)","DOI":"10.1007\/s00417-007-0663-9"},{"issue":"6","key":"781_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","volume":"108","author":"L Calabrese","year":"2000","unstructured":"Calabrese L, Fleicher AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108(6):487\u2013495","journal-title":"Am J Med"},{"key":"781_CR3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0190-9622(95)91549-4","volume":"32","author":"M Carlesimo","year":"1995","unstructured":"Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S (1995) Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Derm 32:866\u2013869","journal-title":"J Am Acad Derm"},{"key":"781_CR4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archopht.1996.01100130413008","volume":"114","author":"Cryotheraphy for Retinopathy of Prematurity Cooperative Group","year":"1996","unstructured":"Cryotheraphy for Retinopathy of Prematurity Cooperative Group (1996) Multicenter trial of cryotheraphy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5\u00bd after randomization. Arch Ophthalmol 114:417\u2013424","journal-title":"Arch Ophthalmol"},{"key":"781_CR5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archopht.119.8.1110","volume":"119","author":"Cryotheraphy for Retinopathy of Prematurity Cooperative Group","year":"2001","unstructured":"Cryotheraphy for Retinopathy of Prematurity Cooperative Group (2001) Multicenter trial of cryotheraphy for retinopathy of prematurity. Ophthalmologic outcomes at 10\u00a0years. Arch Ophthalmol 119:1110\u20131118","journal-title":"Arch Ophthalmol"},{"key":"781_CR6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF00200486","volume":"233","author":"EM Curtis","year":"1995","unstructured":"Curtis EM, Amy L (1995) Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefes Arch Clin Exp Ophthalmol 233:366\u2013370","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"781_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/mvre.1993.1042","volume":"46","author":"R D\u2019Amato","year":"1993","unstructured":"D\u2019Amato R, Weselowsk E, Smith LEH (1993) Microscopic visualization of the retina by angiography with high molecular weight fluorescein labeled dextrans in the mouse. Microvas Res 46:135\u2013142","journal-title":"Microvas Res"},{"key":"781_CR8","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082\u20134085","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"781_CR9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1025618022921","volume":"64","author":"M Gelati","year":"2003","unstructured":"Gelati M, Corsini E, Frigerio S, Pollo B, Broggi G, Croci D (2003) Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol 64(3):193\u2013201","journal-title":"J Neurooncol"},{"issue":"12","key":"781_CR10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.53.12.828","volume":"53","author":"JM Gradner-Medwin","year":"1994","unstructured":"Gradner-Medwin JM, Smith NJ, Powell RJ (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheumatol Disease 53(12):828\u2013832","journal-title":"Ann Rheumatol Disease"},{"issue":"2","key":"781_CR11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/BF00241478","volume":"233","author":"Y Guex-Crosier","year":"1995","unstructured":"Guex-Crosier Y, Pittet N, Herbort CP (1995) The effect of Thalidomide and Sulpidimide on endotoxin-induced uveitis in rats. Graefes Arch Clin Exp Ophthalmol 233(2):990\u2013993","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"781_CR12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1076\/ceyr.18.1.20.5390","volume":"18","author":"RD Higgins","year":"1999","unstructured":"Higgins RD et al (1999) Diltiasem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res 18:20\u201327","journal-title":"Curr Eye Res"},{"issue":"14","key":"781_CR13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/08892220050140892","volume":"16","author":"G Kaplan","year":"2000","unstructured":"Kaplan G, Thomas S, Fierer DS (2000) Thalidomide for the treatment of AIDS- associated wasting. AIDS Res Hum Retroviruses 16(14):1345\u20131355","journal-title":"AIDS Res Hum Retroviruses"},{"key":"781_CR14","first-page":"237","volume":"24","author":"ML Katz","year":"1988","unstructured":"Katz ML, Robison WJ Jr (1988) Autoxidative damage to the retina: potential role in retinopathy of prematurity. Birth Defects Orig Artic Ser 24:237\u2013248","journal-title":"Birth Defects Orig Artic Ser"},{"key":"781_CR15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"BM Kenyon","year":"1997","unstructured":"Kenyon BM, Brown F, D\u2019Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971\u2013978","journal-title":"Exp Eye Res"},{"key":"781_CR16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/BF02112735","volume":"26","author":"F Kohler","year":"1970","unstructured":"Kohler F, Ockenfels H (1970) Teratogene Wirkung der N-Phthalyl-DL-glutamisaure nach intraperitonealern Applikation bei der Maus. Experientia 26:1157\u20131158","journal-title":"Experientia"},{"key":"781_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(62)92665-X","volume":"1","author":"W Lenz","year":"1962","unstructured":"Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1:45","journal-title":"Lancet"},{"key":"781_CR18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","volume":"2","author":"WG McBride","year":"1961","unstructured":"McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1358","journal-title":"Lancet"},{"key":"781_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0306-9877(97)90217-6","volume":"49","author":"MF McCarthy","year":"1997","unstructured":"McCarthy MF (1997) Thalidomide may impede cell migration in primates by down regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 49:123\u2013131","journal-title":"Med Hypotheses"},{"issue":"1","key":"781_CR20","first-page":"283","volume":"42","author":"JS Penn","year":"2001","unstructured":"Penn JS, Rajaratnam VS, Collier RJ, Clark AF (2001) The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42(1):283\u2013290","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"781_CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0045-9380(92)90023-R","volume":"22","author":"DL Phelps","year":"1992","unstructured":"Phelps DL (1992) Retinopathy of prematurity. Curr Probl Pediatr 22:349\u2013371","journal-title":"Curr Probl Pediatr"},{"key":"781_CR22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","volume":"114","author":"EA Pierce","year":"1996","unstructured":"Pierce EA, Foley ED, Smith LE (1996). Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114(10):1219\u20131228","journal-title":"Arch Ophthalmol"},{"key":"781_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0002-9440(10)64714-1","volume":"156","author":"H Sauer","year":"2000","unstructured":"Sauer H, Gunther J, Hescheler J, Wartenberg M (2000) Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathology 156:151\u2013158","journal-title":"Am J Pathology"},{"key":"781_CR24","first-page":"33","volume":"5","author":"WJ Scott","year":"1970","unstructured":"Scott WJ, Fradkin R, Wilson JG (1970) Nonconfirmation of thalidomide induced teratogenesis in rats and mice. Teratology 5:33\u201336","journal-title":"Teratology"},{"key":"781_CR25","first-page":"318","volume":"19","author":"J Sheskin","year":"1980","unstructured":"Sheskin J (1980) The treatment of lepra reactions in lepromatous leprosy. Fifteen years\u2019 experience with thalidomide. Int J Der 19:318\u2013322","journal-title":"Int J Der"},{"key":"781_CR26","first-page":"101","volume":"35","author":"LEH Smith","year":"1994","unstructured":"Smith LEH (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"781_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.eye.6701424","volume":"19","author":"A Spierer","year":"2005","unstructured":"Spierer A, Rabinowitz R, Pri-Chen S, Rosner M (2005) An increase in superoxide dismutase ameliorates oxygen-induced retinopathy in transgenic mice. Eye 19:86\u201391","journal-title":"Eye"},{"key":"781_CR28","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe\u2019er J (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37:290\u2013299","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"127","key":"781_CR29","first-page":"1823","volume":"28","author":"KT Szabo","year":"1967","unstructured":"Szabo KT, Steelman RL (1967) Effects of maternal thalidomide treatment on pregnancy, fetal development, and mortality of the offsprings in random-bred mice. Am J Vet Res 28(127):1823\u20131828","journal-title":"Am J Vet Res"},{"issue":"6","key":"781_CR30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","volume":"35","author":"S Tseng","year":"1996","unstructured":"Tseng S, Pak G, Washenik K (1996) Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35(6):969\u2013979","journal-title":"J Am Acad Dermatol"},{"key":"781_CR31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","volume":"326","author":"GB Vogelsang","year":"1992","unstructured":"Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschoner WE, Jabs DA (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055\u20131058","journal-title":"N Engl J Med"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-008-0781-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0781-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:37Z","timestamp":1559058037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-008-0781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s00417-008-0781-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,15]]}}}